Neuraxis
Neuraxis' revenue rose 32.9% to $4 million in fiscal 2025. Its operating margin was −219.4%, up from −266.5% a year earlier. Free cash flow was −$6 million. The diluted share count rose 31.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Neuraxis lost money in fiscal 2025: a net loss of $8 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Cash and short-term investments | 0 | 0 | 4 | 5 |
| Debt incl. finance leases | 0 | — | — | — |
| Net debt (negative means net cash) | −0 | — | — | — |
| Net debt to EBITDA | — | — | — | — |
| Debt to equity | — | — | — | — |
| Interest coverage | −10.6x | −14.0x | −41.0x | −105.8x |
| Current ratio | 0.1x | 0.1x | 1.8x | 2.0x |
| Quick ratio | 0.1x | 0.1x | 1.7x | 2.0x |
Cash flow
Projections
Project Neuraxis' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 5 insiders bought $1.4 million of Neuraxis shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Apr 1, 2026 | Brian Allen CarricoChief Executive Officer, Director | Bought | 8,060 | $1.96 | $15,798 | Form 4 |
| Apr 1, 2026 | Timothy Robert HenrichsChief Financial Officer | Bought | 7,593 | $1.96 | $14,882 | Form 4 |
| Apr 1, 2026 | Thomas Joeseph CarricoCRO, CCO, Cpo | Bought | 667 | $1.96 | $1,307 | Form 4 |
| Feb 12, 2026 | Brian Hannasch10% owner | Bought | 40,000 | $4.92 | $196,800 | Form 4 |
| Feb 11, 2026 | Brian Hannasch10% owner | Bought | 40,000 | $4.65 | $186,000 | Form 4 |
| Dec 23, 2025 | Gil AharonDirector | Bought | 286,138 | $3.52 | $1.0 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −281.7% | −218.9% | −148.2% |
| Altman Z'' | −420.52 | −45.69 | −36.90 |
| Accruals ratio | −797.2% | −81.4% | −24.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | — | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Fail | Fail |
| Revenue rose relative to assets | — | Pass | Fail |
| F-score | — | — | — |
Compare
Put Neuraxis side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Neuraxis | FY25 | 32.9% | −219.4% | −181.1% | — | — | — | |
| Intelligent Bio Solutions | FY26 | 38.1% | −299.1% | −285.9% | — | — | — | Compare |
| Lucid Diagnostics | FY25 | 8.3% | −1,054.8% | −992.0% | — | — | — | Compare |
| Picard Medical | FY25 | 12.5% | −268.4% | — | — | — | — | Compare |
| Femasys | FY25 | 40.8% | −767.0% | −837.9% | — | — | 2 | Compare |
4 years of figures
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 3 | 2 | 3 | 4 |
| Revenue growth | — | −8.4% | 9.2% | 32.9% |
| Gross profit | 2 | 2 | 2 | 3 |
| Research and development | 0 | 0 | 0 | 0 |
| Operating income | −3 | −7 | −7 | −8 |
| Net income | −5 | −15 | −8 | −8 |
| Diluted EPS (US$) | −2.77 | −4.50 | −1.22 | −0.95 |
| Diluted shares (millions) | 2 | 3 | 7 | 9 |
| Cash flow | ||||
| Cash from operations | −2 | −7 | −6 | −6 |
| Capital expenditure | 0 | 0 | 0 | 0 |
| Free cash flow | −2 | −7 | −6 | −6 |
| Dividends paid | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | — | 0 | 1 |
| Balance sheet at fiscal year end | ||||
| Cash and short-term investments | 0 | 0 | 4 | 5 |
| Debt incl. finance leases | 0 | — | — | — |
| Total assets | 2 | 0 | 5 | 6 |
| Total liabilities | 7 | 2 | 3 | 3 |
| Shareholders' equity | −6 | −1 | 2 | 3 |
| Margins and ratios | ||||
| Gross margin | 88.9% | 87.7% | 86.5% | 84.2% |
| Operating margin | −125.6% | −270.9% | −266.5% | −219.4% |
| Net margin | −178.1% | −594.6% | −306.8% | −218.6% |
| Free cash flow margin | −85.7% | −273.4% | −228.1% | −181.1% |
| Rule of 40 (growth + FCF margin) | — | −281.7% | −218.9% | −148.2% |
| Return on capital | — | — | — | — |
| Return on equity | — | — | −2,480.5% | −285.4% |
| Return on assets | — | −1,469.9% | −312.9% | −139.8% |
| Net debt to EBITDA | — | — | — | — |